Longevity.Technology: The time is right for specialist Longevity investment
Garri Zmudze, Sergey Jakimov, and Ilya Suharenko launch a new fund for longevity research: LongeVC.
Announcements
·
2 min
·
Jul 27
In a recent interview for DealStreet Asia, Garri discussed the international longevity and biotech investing landscape and provided insights on LongeVC’s planned Fund II.
InsightAce Analytic's report states that the longevity and anti-senescence therapy market reached a value of over $27.1 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.8% from 2023 to 2031. Given these figures, investing in the longevity market is more appealing than ever.
In a recent interview with Eudora Wang from DealStreet Asia, Garri discussed the international longevity and biotech investing landscape and provided insights on LongeVC’s planned Fund II. He also revealed details about the upcoming sister fund called AniVC, which will focus on animal longevity and pet health. However, please note that the full interview is available behind a paywall.
Read the full interview here. Please note that the article is behind a paywall.
